Literature DB >> 25728990

The interplay of effector and regulatory T cells in cancer.

Rahul Roychoudhuri1, Robert L Eil2, Nicholas P Restifo3.   

Abstract

Regulatory T (Treg) cells suppress effector T (Teff) cells and prevent immune-mediated rejection of cancer. Much less appreciated are mechanisms by which Teff cells antagonize Treg cells. Herein, we consider how complex reciprocal interactions between Teff and Treg cells shape their population dynamics within tumors. Under states of tolerance, including during tumor escape, suppressed Teff cells support Treg cell populations through antigen-dependent provision of interleukin (IL)-2. During immune activation, Teff cells can lose this supportive capacity and directly antagonize Treg cell populations to neutralize their immunosuppressive function. While this latter state is rarely achieved spontaneously within tumors, we propose that therapeutic induction of immune activation has the potential to stably disrupt immunosuppressive population states resulting in durable cancer regression. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25728990     DOI: 10.1016/j.coi.2015.02.003

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  61 in total

Review 1.  A review of the importance of immune responses in luminal B breast cancer.

Authors:  Delia J Nelson; Briony Clark; Kylie Munyard; Vincent Williams; David Groth; Jespal Gill; Henry Preston; Arlene Chan
Journal:  Oncoimmunology       Date:  2017-01-19       Impact factor: 8.110

Review 2.  Integrative Pharmacology: Advancing Development of Effective Immunotherapies.

Authors:  Mohammad Tabrizi; Daping Zhang; Vaishnavi Ganti; Glareh Azadi
Journal:  AAPS J       Date:  2018-04-27       Impact factor: 4.009

3.  Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model (LSL-Kras(G12D/+) ;LSL-Trp53(R172H/+) ;Pdx-1-Cre), Its Variants, and Their Application in Immuno-oncology Drug Discovery.

Authors:  Jae W Lee; Chad A Komar; Fee Bengsch; Kathleen Graham; Gregory L Beatty
Journal:  Curr Protoc Pharmacol       Date:  2016-06-01

Review 4.  Old dog, new trick: Trivalent arsenic as an immunomodulatory drug.

Authors:  Yishan Ye; Béatrice Gaugler; Mohamad Mohty; Florent Malard
Journal:  Br J Pharmacol       Date:  2020-03-12       Impact factor: 8.739

5.  Deletion of the RNA regulator HuR in tumor-associated microglia and macrophages stimulates anti-tumor immunity and attenuates glioma growth.

Authors:  Jiping Wang; Jianmei W Leavenworth; Anita B Hjelmeland; Reed Smith; Neha Patel; Ben Borg; Ying Si; Peter H King
Journal:  Glia       Date:  2019-08-10       Impact factor: 7.452

6.  Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response.

Authors:  Shilpak Chatterjee; Paramita Chakraborty; Anusara Daenthanasanmak; Supinya Iamsawat; Gabriela Andrejeva; Libia A Luevano; Melissa Wolf; Uday Baliga; Carsten Krieg; Craig C Beeson; Meenal Mehrotra; Elizabeth G Hill; Jeffery C Rathmell; Xue-Zhong Yu; Andrew S Kraft; Shikhar Mehrotra
Journal:  Clin Cancer Res       Date:  2018-10-16       Impact factor: 12.531

7.  Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response.

Authors:  Benjamin M Larimer; Eric Wehrenberg-Klee; Frank Dubois; Anila Mehta; Taylor Kalomeris; Keith Flaherty; Genevieve Boland; Umar Mahmood
Journal:  Cancer Res       Date:  2017-05-01       Impact factor: 12.701

Review 8.  Regulatory T Cells: Central Concepts from Ontogeny to Therapy.

Authors:  Bernard Khor
Journal:  Transfus Med Rev       Date:  2016-07-26

9.  Regulatory T cells with multiple suppressive and potentially pro-tumor activities accumulate in human colorectal cancer.

Authors:  Eleonora Timperi; Ilenia Pacella; Valeria Schinzari; Chiara Focaccetti; Luca Sacco; Francesco Farelli; Roberto Caronna; Gabriella Del Bene; Flavia Longo; Antonio Ciardi; Sergio Morelli; Anna Rita Vestri; Piero Chirletti; Vincenzo Barnaba; Silvia Piconese
Journal:  Oncoimmunology       Date:  2016-04-25       Impact factor: 8.110

10.  Rapid dissemination of RET-transgene-driven melanoma in the presence of non-obese diabetic alleles: Critical roles of Dectin-1 and Nitric-oxide synthase type 2.

Authors:  Emna Dabbeche-Bouricha; Luiza M Araujo; Masashi Kato; Armelle Prévost-Blondel; Henri-Jean Garchon
Journal:  Oncoimmunology       Date:  2015-10-29       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.